REGN News - Candlesense

Regeneron Announces Updated Presentation Time for Upcoming Investor Conference

(NASDAQ:REGN) TARRYTOWN, N.Y., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced today that it will now present at the Morgan Stanley 23rd Annual Global ...

Conference

6 days ago

Regeneron Announces Positive Results from Phase 3 Trial in Generalized Myasthenia Gravis

Cemdisiran monotherapy, dosed subcutaneously every three months, met the primary and key secondary endpoints, showing a 2.3-point placebo-adjusted improvement in Myasthenia Gravis Activities of Dai...

How does Cemdisiran's efficacy and dosing schedule compare to existing treatments and pipeline competitors in the MG space? What is the estimated market size for a subcutaneous Myasthenia Gravis therapy and how might this trial success translate into revenue growth? How will the FDA's review timeline for Cemdisiran affect Regeneron's near‑term valuation?

Clinical trials

16 days ago

EYLEA HD® (aflibercept) Injection 8 mg Applications for Expanded U.S. Label and Prefilled Syringe Receive FDA Review Period Extension

TARRYTOWN, N.Y., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has extended the target action d...

What are the risks of additional regulatory setbacks or a potential rejection, and how might they influence Regeneron's stock volatility and valuation? What is the market potential of the expanded EYLEA HD label and prefilled syringe, and how does it compare to competitors like Lucentis and Beovu? How will the FDA review extension and delayed Q4‑2025 target affect Regeneron's near‑term revenue forecasts and earnings guidance?

Regulatory

22 days ago